-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Insider Selling: Cullinan Oncology, Inc. (NASDAQ:CGEM) Insider Sells $53,200.00 in Stock
Insider Selling: Cullinan Oncology, Inc. (NASDAQ:CGEM) Insider Sells $53,200.00 in Stock
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) insider Jennifer Michaelson sold 4,000 shares of the stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $13.30, for a total transaction of $53,200.00. Following the transaction, the insider now owns 53,031 shares in the company, valued at $705,312.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Jennifer Michaelson also recently made the following trade(s):
Get Cullinan Oncology alerts:- On Tuesday, September 27th, Jennifer Michaelson sold 4,000 shares of Cullinan Oncology stock. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00.
Cullinan Oncology Stock Down 1.4 %
Shares of CGEM opened at $12.26 on Friday. The company has a market cap of $559.20 million, a price-to-earnings ratio of 5.52 and a beta of -0.09. Cullinan Oncology, Inc. has a twelve month low of $7.30 and a twelve month high of $18.46. The company has a 50 day moving average of $12.61 and a two-hundred day moving average of $12.85.
Cullinan Oncology (NASDAQ:CGEM – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.43. On average, sell-side analysts expect that Cullinan Oncology, Inc. will post -3.67 EPS for the current year.Institutional Investors Weigh In On Cullinan Oncology
Institutional investors and hedge funds have recently made changes to their positions in the stock. Rock Springs Capital Management LP lifted its stake in shares of Cullinan Oncology by 1.0% during the first quarter. Rock Springs Capital Management LP now owns 652,578 shares of the company's stock worth $6,832,000 after buying an additional 6,500 shares during the period. Rubric Capital Management LP lifted its stake in shares of Cullinan Oncology by 88.2% during the third quarter. Rubric Capital Management LP now owns 559,737 shares of the company's stock worth $7,176,000 after buying an additional 262,390 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Cullinan Oncology during the third quarter worth $538,000. Nisa Investment Advisors LLC lifted its stake in shares of Cullinan Oncology by 24.0% during the third quarter. Nisa Investment Advisors LLC now owns 17,241 shares of the company's stock worth $222,000 after buying an additional 3,341 shares during the period. Finally, Silverarc Capital Management LLC lifted its stake in shares of Cullinan Oncology by 5.4% during the third quarter. Silverarc Capital Management LLC now owns 224,555 shares of the company's stock worth $2,879,000 after buying an additional 11,465 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Separately, BTIG Research initiated coverage on shares of Cullinan Oncology in a research note on Monday, November 21st. They issued a "buy" rating for the company.
Cullinan Oncology Company Profile
(Get Rating)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
See Also
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Rating) insider Jennifer Michaelson sold 4,000 shares of the stock in a transaction that occurred on Friday, November 25th. The shares were sold at an average price of $13.30, for a total transaction of $53,200.00. Following the transaction, the insider now owns 53,031 shares in the company, valued at $705,312.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
庫利南腫瘤公司(納斯達克代碼:CGEM-GET Rating)內部人士詹妮弗·邁克爾森在11月25日(星期五)的一筆交易中出售了4,000股該股。這些股票以13.30美元的平均價格出售,總成交額為53,200.00美元。交易完成後,這位內部人士現在擁有該公司53,031股,價值705,312.30美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過這個環節.
Jennifer Michaelson also recently made the following trade(s):
詹妮弗·邁克爾森最近還做了以下交易:
- On Tuesday, September 27th, Jennifer Michaelson sold 4,000 shares of Cullinan Oncology stock. The shares were sold at an average price of $12.40, for a total transaction of $49,600.00.
- 9月27日,星期二,詹妮弗·邁克爾森出售了4,000股庫利南腫瘤公司的股票。這些股票以12.40美元的平均價格出售,總成交額為49,600.00美元。
Cullinan Oncology Stock Down 1.4 %
庫利南腫瘤學股票下跌1.4%
Shares of CGEM opened at $12.26 on Friday. The company has a market cap of $559.20 million, a price-to-earnings ratio of 5.52 and a beta of -0.09. Cullinan Oncology, Inc. has a twelve month low of $7.30 and a twelve month high of $18.46. The company has a 50 day moving average of $12.61 and a two-hundred day moving average of $12.85.
上週五,CGEM的股價開盤報12.26美元。該公司市值為5.592億美元,市盈率為5.52倍,貝塔係數為-0.09。庫利南腫瘤公司的股價為7.30美元的12個月低點和18.46美元的12個月高位。該公司的50日移動均線切入位在12.61美元,200日移動均線切入位在12.85美元。
Institutional Investors Weigh In On Cullinan Oncology
機構投資者參與庫利南腫瘤學
Institutional investors and hedge funds have recently made changes to their positions in the stock. Rock Springs Capital Management LP lifted its stake in shares of Cullinan Oncology by 1.0% during the first quarter. Rock Springs Capital Management LP now owns 652,578 shares of the company's stock worth $6,832,000 after buying an additional 6,500 shares during the period. Rubric Capital Management LP lifted its stake in shares of Cullinan Oncology by 88.2% during the third quarter. Rubric Capital Management LP now owns 559,737 shares of the company's stock worth $7,176,000 after buying an additional 262,390 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Cullinan Oncology during the third quarter worth $538,000. Nisa Investment Advisors LLC lifted its stake in shares of Cullinan Oncology by 24.0% during the third quarter. Nisa Investment Advisors LLC now owns 17,241 shares of the company's stock worth $222,000 after buying an additional 3,341 shares during the period. Finally, Silverarc Capital Management LLC lifted its stake in shares of Cullinan Oncology by 5.4% during the third quarter. Silverarc Capital Management LLC now owns 224,555 shares of the company's stock worth $2,879,000 after buying an additional 11,465 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.
機構投資者和對衝基金最近改變了他們在該股的頭寸。Rock Springs Capital Management LP在第一季度增持了Cullinan Oncology的股份1.0%。Rock Springs Capital Management LP現在擁有652,578股該公司股票,價值6,832,000美元,在此期間又購買了6,500股。Rubric Capital Management LP在第三季度增持了Cullinan Oncology股票88.2%。在此期間,Rbric Capital Management LP額外購買了262,390股,目前擁有559,737股該公司股票,價值7,176,000美元。勝利資本管理公司在第三季度收購了庫利南腫瘤公司價值53.8萬美元的新股份。第三季度,NISA Investment Advisors LLC將其在Cullinan Oncology的持股比例提高了24.0%。NISA Investment Advisors LLC現在持有該公司17,241股股票,價值22.2萬美元,在此期間又購買了3,341股。最後,SilverarcCapital Management LLC在第三季度將其在Cullinan Oncology的股份增加了5.4%。SilverarcCapital Management LLC現在擁有224,555股該公司的股票,價值2,879,000美元,在此期間又購買了11,465股。82.53%的股票目前由機構投資者和對衝基金持有。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, BTIG Research initiated coverage on shares of Cullinan Oncology in a research note on Monday, November 21st. They issued a "buy" rating for the company.
另外,BTIG Research在11月21日星期一的一份研究報告中啟動了對庫利南腫瘤學股票的報道。他們對該公司的評級為“買入”。
Cullinan Oncology Company Profile
庫利南腫瘤學公司簡介
(Get Rating)
(獲取評級)
Cullinan Oncology Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
庫利南腫瘤公司是一家生物製藥公司,專注於為美國的癌症患者開發一系列靶向腫瘤學和免疫腫瘤學療法。該公司的主要候選藥物是CLN-081,這是一種口服小分子藥物,正在進行I/IIa期劑量升級和擴大試驗,用於治療非小細胞肺癌患者。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Cullinan Oncology (CGEM)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
- 免費獲取StockNews.com關於庫利南腫瘤學的研究報告(CGEM)
- 福特在英國工廠加速生產電動汽車動力裝置
- 賣空者對馬倫汽車股票的看法仍然正確嗎?
- La-Z-Boy傾斜到更舒適的水平
- 蘋果會在年底前大漲嗎?
- 復甦集會是為SoFi而來的嗎?
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受庫利南腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對庫利南腫瘤學和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧